Purple Biotech (PPBT) Non Operating Income (2014 - 2026)
Purple Biotech (PPBT) posted quarterly Non Operating Income of -$2.2 million for Q1 2026, down 127.58% year-over-year from $7.8 million in Q1 2025, and down 1197.46% quarter-over-quarter from $197000.0 in Q4 2025.
Purple Biotech (PPBT) Non Operating Income (2014 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Non Operating Income for 12 consecutive years, with -$2.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income fell 127.58% year-over-year to -$2.2 million; the TTM figure through Mar 2026 stood at -$2.2 million (up 45.55% YoY), while the FY2025 annual figure was $966000.0, down 74.07% from the prior year.
- Non Operating Income retreated to -$2.2 million in Q1 2026 per PPBT's latest filing, from $197000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $197000.0 in Q4 2025 and bottomed at -$2.2 million in Q1 2026.
- Historically, Non Operating Income has averaged -$613066.7 across 5 years, with a median of -$601000.0 in 2024.
- Annual changes were most pronounced in 2023 — Non Operating Income surged 165.79% — and 2024, when it plunged 4000.0%.
- Purple Biotech's Non Operating Income stood at -$38000.0 in 2022, then slumped by 3605.26% to -$1.4 million in 2023, then soared by 57.32% to -$601000.0 in 2024, then surged by 132.78% to $197000.0 in 2025, then plunged by 1197.46% to -$2.2 million in 2026.
- Business Quant data shows PPBT's Non Operating Income at -$2.2 million in Q1 2026, $197000.0 in Q4 2025, and -$62000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Purple Biotech | 130.35 | 130.35 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.16 Mn |
| Dec 31, 2025 | 197,000.00 |
| Sep 30, 2025 | -62,000.00 |
| Jun 30, 2025 | -146,000.00 |
| Mar 31, 2025 | -950,000.00 |
| Dec 31, 2024 | -601,000.00 |
| Sep 30, 2024 | -1.47 Mn |
| Jun 30, 2024 | -975,000.00 |
| Mar 31, 2024 | -685,000.00 |
| Dec 31, 2023 | -1.41 Mn |
| Sep 30, 2023 | -692,000.00 |
| Jun 30, 2023 | 25,000.00 |
| Mar 31, 2023 | -219,000.00 |
| Jun 30, 2022 | -38,000.00 |
| Mar 31, 2022 | -15,000.00 |
| Dec 31, 2021 | -34,000.00 |
| Sep 30, 2021 | -47,000.00 |
| Jun 30, 2021 | 24,000.00 |
| Mar 31, 2021 | -98,000.00 |
| Dec 31, 2020 | -8.05 Mn |